Skip to content
Indiatimes Hosting

Home

Category: biotech issuesSyndicate content

Interim Safety and Risk Assessment of Melamine and its Analogues in Food for Humans

October 7, 2008 by vikas

vikas's picture
0
No votes yet
Your rating: None

On September 11, 2008, FDA learned that melamine may be contained in an infant formula manufactured by a firm in China. As of September 21, 2008, FDA learned that a total of 52,857 cases of nephrolithiasis (and, in some instances, renal failure) had been reported in China linked to consumption of this contaminated powdered formula.

  • Login or register to post comments
  • Read more
  • 59 reads

Disappointing biotech

October 6, 2008 by dadmin

dadmin's picture
3
Average: 3 (1 vote)
Your rating: None

Biotechnology offered the hope of cheaper and better drugs. Analysis of biotech products licensed in Europe shows the reality is somewhat different

  • Login or register to post comments
  • Read more
  • 41 reads

Biotech, the environment and the three Ps

October 6, 2008 by dadmin

dadmin's picture
5
Average: 5 (1 vote)
Your rating: None

To answer your first question: the three Ps in the title stand for people, profit and preservation. I must admit that when I was asked to participate in a discussion on 'The Biotechnology Industry and the Environment' at the recent BioVision conference in Lyon, France, I did not immediately think of the three Ps.

  • Login or register to post comments
  • Read more
  • 59 reads

Alternatives to Protein Biologics

October 3, 2008 by vikas

vikas's picture
3.5
Average: 3.5 (2 votes)
Your rating: None

It should be noted that there may be alternative drugs to those biological materials produced by gene manipulation and expression. This will be especially relevant if the high cost of bioengineered compounds becomes unacceptable to society as a whole. The point is that proteins may have unique biological activities that can be mimicked in some cases by small molecular weight compounds, in other words, conventional drugs. At present there are few examples of this type of activity but research has already been initiated—and, who knows, this may have a successful outcome.

  • Login or register to post comments
  • Read more
  • 51 reads

Generic Biotechnological Drug Issues

October 3, 2008 by vikas

vikas's picture
3.5
Average: 3.5 (2 votes)
Your rating: None

The respected scientific journalist W. Wayt Gibbs, writing in Scientific American (2003), has suggested that many of the issues associated with concerns about the high costs of individual bioengineered protein drugs will go away when the patents lapse and generic drug manufacturers become involved.

  • Login or register to post comments
  • Read more
  • 35 reads

Latest Biotech Discussions

Archive Syndicate content
AdaptiveThemes